Table 3.
Common Name | No. of Cohorts | Behavior (Up-Down-Equal) |
Vote-Counting | N | Reference |
---|---|---|---|---|---|
CRC and Advanced Adenoma vs. Control | |||||
N1,N12-Diacetylspermine | 3 | 3–0–0 | 3 | 928 | [24,25] ɫ |
D-Glucose | 2 | 2–0–0 | 2 | 696 | [24] ɫ |
L-Kynurenine | 2 | 2–0–0 | 2 | 696 | [24] ɫ |
L-Proline | 2 | 2–0–0 | 2 | 696 | [24] ɫ |
Creatinine | 2 | 0–2–0 | −2 | 452 | [35,36] |
Phenol | 2 | 0–2–0 | −2 | 294 | [29,35] |
Putrescine | 3 | 2–0–1 | 2 | 900 | [24,35] ɫ |
Hippuric acid | 4 | 0–3–1 | −3 | 1148 | [24,35,36] ɫ |
Indole-3-acetic acid | 3 | 0–2–1 | −2 | 900 | [24,35] ɫ |
Citric acid | 5 | 1–3–1 | −2 | 1271 | [24,35,36,43] ɫ |
P-Cresol | 2 | 1–1–0 | 1 | 417 | [35,43] |
Tetradecenoyl carnitine (C14:1) | 2 | 1–0–1 | 1 | 696 | [24] ɫ |
2-Aminohexanedioic acid | 2 | 0–1–1 | −1 | 696 | [24] ɫ |
3-(3-Hydroxyohenyl)-3-hydroxypropanoic acid | 2 | 0–1–1 | −1 | 696 | [24] ɫ |
Aspartic acid | 2 | 0–1–1 | −1 | 696 | [24] ɫ |
3-Hidroxybutyric acid | 2 | 1–1–0 | 0 | 696 | [24] ɫ |
Butyric acid | 2 | 1–1–0 | 0 | 696 | [24] ɫ |
Hydroxyproline | 2 | 1–1–0 | 0 | 696 | [24] ɫ |
L-Alanine | 2 | 1–1–0 | 0 | 452 | [35,36] |
L-Dopa | 2 | 1–1–0 | 0 | 696 | [24] ɫ |
L-Tryptophan | 2 | 1–1–0 | 0 | 327 | [35,43] |
Urea | 2 | 1–1–0 | 0 | 452 | [35,36] |
CRC Stage vs. Control | |||||
Hippuric acid | 2 | 1–1–0 | 0 | 248 | [37,44] |
Pre-surgery vs. Post-surgery | |||||
Salicyluric acid | 2 | 0–2–0 | −2 | 258 | [43,44] |
Asparagine | 2 | 1–1–0 | 0 | 258 | [43,44] |
Citrate | 2 | 1–1–0 | 0 | 258 | [43,44] |
Tyrosine | 2 | 1–1–0 | 0 | 246 | [43,44] |
ɫ Reference [24] has two cohorts for this is included twice.